← Leaderboards
Tahseen Mozaffar
University Of California, San Diego
$6,022,771
Attributed
$6,250,034
Total exposure
15
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,250,034 · 15
By mechanism
R01$4,186,266 · 1
U24$1,545,000 · 1
T32$340,894 · 1
M01$177,874 · 12
Top collaborators
- Sergio A Villalta2 shared
- Kyoko Yokomori2 shared
Others in their field
Top investigators on “Research Personnel”
- David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$364,053,504
- Judith S. Currier · University Of California Los Angeles$284,675,012
Research focus
Research PersonnelInstitutionResourcesGrantFundingSiteClinical TrialsEnrollmentGenerationsBiological MarkersSourceTrial DesignInterestAmyotrophic Lateral SclerosisComputer Retrieval Of Information On Scientific Projects DatabaseInstitutional Review BoardsUnited States National Institutes Of HealthCohortMuscleLeadAgingFollow-UpEvaluationMuscle Weakness
Grant awards (24)
Influence of NT5c1A antibodies on disease progression, clinical phenotype and blood and muscle biomarkers in sporadic Inclusion Body Myositis - A prospective evaluation$359,826
R01 · FY2025 · AR · contact PI
MAXIMUS: MAXimizing Training in MUScle Research$237,956
T32 · FY2025 · AR
Influence of NT5c1A antibodies on disease progression, clinical phenotype and blood and muscle biomarkers in sporadic Inclusion Body Myositis - A prospective evaluation$567,123
R01 · FY2024 · AR · contact PI
MAXIMUS: MAXimizing Training in MUScle Research$102,938
T32 · FY2024 · AR
Influence of NT5c1A antibodies on disease progression, clinical phenotype and blood and muscle biomarkers in sporadic Inclusion Body Myositis - A prospective evaluation$960,345
R01 · FY2023 · AR · contact PI
Influence of NT5c1A antibodies on disease progression, clinical phenotype and blood and muscle biomarkers in sporadic Inclusion Body Myositis - A prospective evaluation$1,159,032
R01 · FY2022 · AR · contact PI
UCI-NEXT, a NeuroNEXT site$309,000
U24 · FY2022 · NS · contact PI
Influence of NT5c1A antibodies on disease progression, clinical phenotype and blood and muscle biomarkers in sporadic Inclusion Body Myositis - A prospective evaluation$1,139,940
R01 · FY2021 · AR · contact PI
UCI-NEXT, a NeuroNEXT site$309,000
U24 · FY2021 · NS · contact PI
UCI-NEXT, a NeuroNEXT site$309,000
U24 · FY2020 · NS · contact PI
UCI-NEXT, a NeuroNEXT site$309,000
U24 · FY2019 · NS · contact PI
UCI-NEXT, a NeuroNEXT site$309,000
U24 · FY2018 · NS · contact PI
A MULTICENTER STUDY FOR THE VALIDATION OF ALS BIOMARKERS$345
M01 · FY2010 · RR · contact PI
COMBINATION DRUG SELECTION TRIAL IN AMYOTROPHIC LATERAL SCLEROSIS$5,495
M01 · FY2008 · RR · contact PI
OPEN LABEL EXTENSION OF PROTOCOL AALS-001 (#AALS-001-OL) - ARIMOCLOMOL IN AMY$1,831
M01 · FY2008 · RR · contact PI
A MULTI-CENTER, PHASE III, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, CLINIC$1,374
M01 · FY2008 · RR · contact PI
A MULTI-CENTER, PHASE III, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, CLINIC$43,024
M01 · FY2007 · RR · contact PI
A MULTICENTER, DOSE RANGING SAFETY AND PHARMACOKINETICS STUDY OF ARIMOCLOMOL IN)$20,155
M01 · FY2007 · RR · contact PI
AMYOTROPHIC LATERAL SCLEROSIS RESEARCH GROUP [ALS RG] COLLECTION OF DATA AND BI$16,667
M01 · FY2007 · RR · contact PI
OPEN LABEL EXTENSION OF PROTOCOL AALS-001 (#AALS-001-OL) - ARIMOCLOMOL IN AMY$10,465
M01 · FY2007 · RR · contact PI
RESEQUENCING THE VARIABLE HUMAN GENOME IN SPORADIC ALS: A NECESSARY PRELUDE TO$10,078
M01 · FY2007 · RR · contact PI
COMBINATION DRUG SELECTION TRIAL IN AMYOTROPHIC LATERAL SCLEROSIS$8,527
M01 · FY2007 · RR · contact PI
A MULTI-CENTER, PHASE III, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, CLINIC$58,336
M01 · FY2006 · RR · contact PI
A MULTICENTER, DOSE RANGING SAFETY AND PHARMACOKINETICS STUDY OF ARIMOCLOMOL IN)$1,577
M01 · FY2006 · RR · contact PI